<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04951986</url>
  </required_header>
  <id_info>
    <org_study_id>HREC REF: 001/2021</org_study_id>
    <nct_id>NCT04951986</nct_id>
  </id_info>
  <brief_title>Testing New Strategies for Patients Hospitalised With HIV-associated Disseminated Tuberculosis</brief_title>
  <acronym>NEW-STRAT TB</acronym>
  <official_title>Testing New Strategies for Patients Hospitalised With HIV-associated Disseminated Tuberculosis</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>University of Cape Town</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>University of Cape Town</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      The New Strat-TB trial is a superiority Phase III randomised control clinical trial with a&#xD;
      2X2 factorial design. The main aim of the study is to assess the efficacy and safety of high&#xD;
      dose rifampicin and levofloxacin for 14 days in addition to standard TB therapy with or&#xD;
      without steroids among adults hospitalized with HIV-associated disseminated tuberculosis.&#xD;
&#xD;
      The investigators hypothesize that intensified treatment with increased rifampicin doses at&#xD;
      35 mg/kg plus levofloxacin will more rapidly reduce the mycobacterial load. The investigators&#xD;
      also hypothesize that steroids will have an immune-modulatory effect and dampen the&#xD;
      activation of the innate immune system. The investigators hypothesize that these two&#xD;
      strategies will lead to improved survival in patients hospitalized with HIV-associated&#xD;
      disseminated tuberculosis.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Primary efficacy endpoint:&#xD;
&#xD;
      All-cause mortality at 12 weeks&#xD;
&#xD;
      Secondary efficacy endpoint:&#xD;
&#xD;
      All-cause mortality at 2 and 24 weeks&#xD;
&#xD;
      Safety and tolerability endpoints:&#xD;
&#xD;
        -  Occurrence of hepatotoxicity using the American Thoracic Society (ATS) hepatotoxicity&#xD;
           criteria: Alanine aminotransferase (ALT) elevation of more than three times the upper&#xD;
           limit of normal (ULN) in the presence of hepatitis symptoms and/or jaundice or five&#xD;
           times the upper limit of normal in the absence of symptoms.&#xD;
&#xD;
        -  Corticosteroid-associated adverse events, classified by severity and relation to study&#xD;
           drug and will be reported if these develop within 4 weeks of enrolment. These will&#xD;
           include new hypertension, new poor blood pressure control in a known hypertensive,&#xD;
           hyperglycaemia, hypomania, mania, depression, acne, gastritis symptoms, upper&#xD;
           gastrointestinal bleeding, and avascular bone necrosis.&#xD;
&#xD;
        -  Laboratory safety data (Grade 3 and 4 abnormalities using the ACTG grading system):&#xD;
           liver function tests (alanine and aspartate aminotransferase[ALT, AST], gammaglutamyl&#xD;
           transferase [GGT], alkaline phosphatase [ALP], International Normalized Ratio [INR],&#xD;
           conjugated and total bilirubin [CBR, TBR]), glucose, full blood counts (including white&#xD;
           cell, neutrophil and platelet counts plus haemoglobin) and electrolytes (sodium,&#xD;
           potassium) and creatinine.&#xD;
&#xD;
        -  Occurrence of other opportunistic infections (AIDS-related, bacterial, fungal and viral)&#xD;
           and malignancies (Kaposi's sarcoma) up to 12 weeks.&#xD;
&#xD;
        -  Occurrence of paradoxical tuberculosis immune reconstitution inflammatory syndrome&#xD;
           (TB-IRIS) in patients starting antiretroviral therapy up to 12 weeks.&#xD;
&#xD;
        -  All grade 3 and 4 clinical adverse events (using the ACTG grading system)&#xD;
&#xD;
        -  Serious adverse events&#xD;
&#xD;
        -  Adverse events requiring study drug interruption and or withdrawal&#xD;
&#xD;
        -  Adverse drug reactions attributed to study drug&#xD;
&#xD;
      Follow-up:&#xD;
&#xD;
      Participants will be followed up daily while admitted to hospital for assessment of adverse&#xD;
      events. Safety and routine blood tests will be done on day 2, 4, 7, 14 and 28. Further visits&#xD;
      will be on week 12 and 24.&#xD;
&#xD;
      Data monitoring:&#xD;
&#xD;
      The trial will be monitored by an independent Data and Safety Monitoring Board (DSMB)&#xD;
      comprising 4 independent researchers and an independent statistician. If there is evidence of&#xD;
      harm related to study medication or trial conduct the DSMB may advise the sponsor that trial&#xD;
      enrolment should be stopped.&#xD;
&#xD;
      Clinical trial site:&#xD;
&#xD;
      Mitchells Plain Hospital and Khayelitsha Hospital&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Not yet recruiting</overall_status>
  <start_date type="Anticipated">July 15, 2021</start_date>
  <completion_date type="Anticipated">December 31, 2024</completion_date>
  <primary_completion_date type="Anticipated">June 30, 2024</primary_completion_date>
  <phase>Phase 3</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Factorial Assignment</intervention_model>
    <intervention_model_description>First intervention (open label):&#xD;
a) Experimental arm: Standard first-line anti-tuberculosis therapy plus additional rifampicin to reach 35mg/kg/day for 14 days plus levofloxacin 750mg/day for weight &lt;50kg and 1g/day for weight &gt;50kg for 14 days b) Control arm: Standard TB therapy containing rifampicin 10mg/kg for 14 days (standard of care) After 14 days both study arms will continue standard TB therapy with rifampicin at 10mg/kg to complete 2 months of intensive phase in total. This will be followed by standard continuation phase TB therapy.&#xD;
2. Second intervention (double-blind):&#xD;
Experimental arm: Prednisone 1.5mg/kg per day for 14 days&#xD;
Control arm: Identical placebo for 14 days</intervention_model_description>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>All-cause mortality</measure>
    <time_frame>12 weeks</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>In-hospital mortality during index admission</measure>
    <time_frame>7 days</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>All-cause mortality</measure>
    <time_frame>2 and 24 weeks respectively</time_frame>
  </secondary_outcome>
  <number_of_arms>4</number_of_arms>
  <enrollment type="Anticipated">732</enrollment>
  <condition>Disseminated Tuberculosis</condition>
  <condition>HIV</condition>
  <arm_group>
    <arm_group_label>High dose Rifampicin plus Levofloxacin</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Standard TB treatment plus additional Rifampicin 35 mg/kg/day PLUS Levofloxacin for 14 days</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Prednisone</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Prednisone 1.5 mg/kg for 14 days</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Standard TB treatment</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>High dose rifampicin/levofloxacin comparator</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Placebo</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>Prednisone comparator</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Rifampin</intervention_name>
    <description>Rifampicin up to 35 mg/kg/day for 14 days</description>
    <arm_group_label>High dose Rifampicin plus Levofloxacin</arm_group_label>
    <other_name>rifampicin</other_name>
    <other_name>Rifadin</other_name>
    <other_name>Rimactane</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Levofloxacin</intervention_name>
    <description>Levofloxacin 750mg daily (for weight &lt;50kg) or 1 g daily (for weight &gt;50 kg) daily for 14 days</description>
    <arm_group_label>High dose Rifampicin plus Levofloxacin</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Rifampicin, Pyrazinamide, Ethambutol and Isoniazid</intervention_name>
    <description>Rifampicin 10 mg/kg; Isoniazid 5 mg/kg; Pyrazinamide 15 mg/kg; Ethambutol15 mg/kg in fixed dose combination administered per weight band. Standard of care control arm</description>
    <arm_group_label>High dose Rifampicin plus Levofloxacin</arm_group_label>
    <arm_group_label>Standard TB treatment</arm_group_label>
    <other_name>Rifafour</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Prednisone</intervention_name>
    <description>Prednisone 1.5mg/kg/day for 14 days</description>
    <arm_group_label>Prednisone</arm_group_label>
    <other_name>Trolic</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Placebo</intervention_name>
    <description>Placebo identical to Prednisone</description>
    <arm_group_label>Placebo</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Aged &gt;18&#xD;
&#xD;
          -  HIV infection&#xD;
&#xD;
          -  Disseminated TB confirmed by one or more of the following tests being positive&#xD;
&#xD;
               1. Lysed blood Xpert Ultra positive for MTB&#xD;
&#xD;
               2. Concentrated urine Xpert Ultra positive for MTB&#xD;
&#xD;
               3. Urine Alere LAM positive&#xD;
&#xD;
          -  Hospital clinical team made decision to initiate TB treatment&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Pregnant or breastfeeding&#xD;
&#xD;
          -  Active or recent SARS-CoV-2 infection&#xD;
&#xD;
          -  TB treatment within the last 1 month or more than 2 doses of TB treatment&#xD;
&#xD;
          -  Rifampicin resistance&#xD;
&#xD;
          -  Neurological TB&#xD;
&#xD;
          -  Receiving corticosteroids or other immunosuppressive therapy&#xD;
&#xD;
          -  ALT &gt;120 IU/L or total bilirubin &gt;34 Î¼mol/L&#xD;
&#xD;
          -  Plasma CrAg positive or cryptococcal meningitis&#xD;
&#xD;
          -  Current malignancy requiring active treatment (including any Kaposi sarcoma lesions)&#xD;
&#xD;
          -  Patients established on ART with Protease Inhibitor based regimen who cannot be&#xD;
             switched to a dolutegravir based regimen&#xD;
&#xD;
          -  Diabetic ketoacidosis or Hyperosmolar Non-ketotic acidosis&#xD;
&#xD;
          -  Any condition in the opinion of the investigator for which participation would&#xD;
             increase risk to the patient&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_contact>
    <last_name>Charlotte Schutz, PhD</last_name>
    <phone>+27 (0)21 406 6797</phone>
    <email>charlotte.schutz@uct.ac.za</email>
  </overall_contact>
  <location>
    <facility>
      <name>Wellcome Centre for Infectious Disease Research in Africa (CIDRI-Africa)</name>
      <address>
        <city>Cape Town</city>
        <state>Western Cape</state>
        <zip>7925</zip>
        <country>South Africa</country>
      </address>
    </facility>
    <contact>
      <last_name>Charlotte Schutz, PhD</last_name>
      <email>charlotte.schutz@uct.ac.za</email>
    </contact>
  </location>
  <location_countries>
    <country>South Africa</country>
  </location_countries>
  <verification_date>July 2021</verification_date>
  <study_first_submitted>June 30, 2021</study_first_submitted>
  <study_first_submitted_qc>June 30, 2021</study_first_submitted_qc>
  <study_first_posted type="Actual">July 7, 2021</study_first_posted>
  <last_update_submitted>July 8, 2021</last_update_submitted>
  <last_update_submitted_qc>July 8, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">July 15, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>University of Cape Town</investigator_affiliation>
    <investigator_full_name>Charlotte Schutz</investigator_full_name>
    <investigator_title>Co-Principal Investigator</investigator_title>
  </responsible_party>
  <keyword>HIV</keyword>
  <keyword>High dose rifampicin</keyword>
  <keyword>Fluoroquinolones</keyword>
  <keyword>Glucocorticoids</keyword>
  <keyword>Antiretroviral therapy</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Tuberculosis</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Levofloxacin</mesh_term>
    <mesh_term>Ofloxacin</mesh_term>
    <mesh_term>Rifampin</mesh_term>
    <mesh_term>Isoniazid</mesh_term>
    <mesh_term>Pyrazinamide</mesh_term>
    <mesh_term>Ethambutol</mesh_term>
    <mesh_term>Prednisone</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>Yes</sharing_ipd>
    <ipd_description>IPD will be shared on request, after discussion with ethics committee</ipd_description>
    <ipd_info_type>Study Protocol</ipd_info_type>
    <ipd_info_type>Statistical Analysis Plan (SAP)</ipd_info_type>
    <ipd_info_type>Informed Consent Form (ICF)</ipd_info_type>
    <ipd_info_type>Analytic Code</ipd_info_type>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

